3 recruiting, 2 not yet recruiting, 1 active not recruiting, 1 unknown. 3 Phase 3, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Adjuvant immunotherapy: new trials by email Literature Review of Adjuvant immunotherapy trials Research Report on Adjuvant immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy - Resectable Stage II-IIIa NSCLC | Phase 3 | Recruiting | Fudan University | 759 | 2026-05-01 | 2026-09-10 |
| De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma De-escalation surgery, Standard Surgery, radiotherapy - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 356 | 2026-01-01 | 2026-01-06 |
| Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel - Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2025-09-20 | 2025-08-28 |
| NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC Neoadjuvant Chemoradiotherapy, neoadjuvant immunotherapy, Surgery - Esophageal Squamous Cell Carcinoma (ESCC) | Not applicable | Active not recruiting | RenJi Hospital | 50 | 2024-10-30 | 2025-01-07 |
| Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma Reduced-target resection, Full-target resection, Adjuvant immunotherapy - Nasopharyngeal Carcinoma, De-escaltion Therapy | Phase 3 | Recruiting | Sun Yat-sen University | 424 | 2023-05-20 | 2023-05-26 |
| Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC endoscopic surgery - Recurrent Nasopharyngeal Carcinoma | Phase 2 | Unknown | Eye & ENT Hospital of Fudan University | 77 | 2022-05-08 | 2022-05-10 |
| Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma Adjuvant chemotherapy, adjuvant immunotherapy - Muscle Invasive Upper Tract Urothelial Carcinoma | Recruiting | RenJi Hospital | 84 | 2022-02-01 | 2025-12-09 |
Nasopharyngeal Carcinoma (2) · Esophageal Squamous Cell Carcinoma (1) · Lung Neoplasms (1) · Neoplasm, Residual (1) · Squamous Cell Carcinoma of Head and Neck (1)
RenJi Hospital (2) · Sun Yat-sen University (2) · Eye & ENT Hospital of Fudan University (1) · Fudan University (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
China (7)
Hongmeng Yu, MD,PHD (1) · Ming-Yuan Chen, MD, PhD (1) · Yujie Liang (1)
PMID 15825201, PMID 18486742, PMID 18784101, PMID 23129742, PMID 27718784, PMID 30509740, PMID 31679945, PMID 33243985, PMID 34473219, PMID 35585121, PMID 35766967, PMID 37395170, PMID 37991778, PMID 38110599, PMID 38467604